U.S. Department of Health and Human Services (HHS) announced advanced Notice of Termination of the C

Data from LIBERTY can provide important insight into the VYD2311 clinical profile by direct comparis

HC Wainwright & Co. analyst Patrick R. Trucchio reiterates Invivyd (NASDAQ:IVVD) with a Buy a

LIBERTY clinical trial will evaluate the comparative safety and tolerability of VYD2311 versus mRNA

DECLARATION is a Phase 3, randomized, placebo-controlled clinical trial to evaluate the safety and e

Dow Jones falls 400 points, while Gemini Space Station Inc (NASDAQ: GEMI) sees 25.7% jump after stro

Invivyd (NASDAQ:IVVD) reported quarterly losses of $(0.13) per share which missed the analyst consen

Invivyd authors evaluated early side effects of prior low-dose investigational monoclonal antibody a

U.S. stocks fell, Dow Jones down 100+ points. BlackBerry (NYSE:BB) reported strong Q4 results and sa

Invivyd expands VYD2311 COVID study, delays timeline to Q3 2026, and advances measles antibody VMS06

Confirmed, pooled, blinded COVID-19 events in the ongoing Phase 3 DECLARATION study of VYD2311 accum

U.S. stock futures lower, with Dow futures down over 1%. BETA Technologies (NYSE: BETA) fell in pre-